TAT-11: 212Pb-NNV003 as a Novel Targeted Alpha Therapy for CD37 Positive B-cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Ottawa, ON, Canada (UroToday.com) The toxicity of Pb212-NNV003 (an anti-CD37 antibody from Nordic Nanovector) was first evaluated in tumor-free mice. No hemotoxicity was observed except for a slight reduction in platelets, which recovered. Next mice were injected with either lymphoma (Daudi) or leukemia (MC2) cells. Pb212-NNV003 was injected at a single dose of 10,15, or 20 microCi.

There was a significant increase in median survival at all doses compared to controls of saline, cold NNV002, or Pb212Cetuximabb. At the respective doses 70%, 90% and 100% of mice injected with MEC-2 cells were tumor-free 20 weeks post cell injection compared with a median survival of 4.9, 5.4 and 9.3 weeks in the control samples. Similar results were obtained with the Daudi cells.

Presented by: Amal Saidi, PhD, Orano Med, Plano, Texas, United States

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.